Recent Investment Analysts’ Ratings Updates for Crinetics Pharmaceuticals (CRNX)

Crinetics Pharmaceuticals (NASDAQ: CRNX) recently received a number of ratings updates from brokerages and research firms:

• 7/17/2026 – Crinetics Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/12/2026 – Crinetics Pharmaceuticals was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 7/8/2026 – Crinetics Pharmaceuticals was downgraded by TD Cowen from “buy” to “hold”.
• 7/7/2026 – Crinetics Pharmaceuticals was downgraded by Evercore Inc from “strong-buy” to “hold”.
• 7/7/2026 – Crinetics Pharmaceuticals was downgraded by Citizens Jmp from “strong-buy” to “hold”.
• 7/7/2026 – Crinetics Pharmaceuticals was downgraded by Piper Sandler from “strong-buy” to “hold”.
• 7/7/2026 – Crinetics Pharmaceuticals was downgraded by Lifesci Capital from “strong-buy” to “hold”.
• 7/7/2026 – Crinetics Pharmaceuticals was downgraded by JonesTrading from “buy” to “hold”. They now have a $85.00 price target on the stock.
• 7/7/2026 – Crinetics Pharmaceuticals was downgraded by Jefferies Financial Group Inc. from “buy” to “hold”. They now have a $85.00 price target on the stock, up from $55.00.
• 7/7/2026 – Crinetics Pharmaceuticals had its “market perform” rating reaffirmed by Oppenheimer Holdings, Inc..
• 7/7/2026 – Crinetics Pharmaceuticals had its price target raised by Robert W. Baird from $62.00 to $85.00. They now have an “outperform” rating on the stock.
• 7/7/2026 – Crinetics Pharmaceuticals was downgraded by HC Wainwright from “buy” to “hold”. They now have a $85.00 price target on the stock, up from $81.00.
• 7/7/2026 – Crinetics Pharmaceuticals was downgraded by Cantor Fitzgerald from “overweight” to “hold”.
• 7/2/2026 – Crinetics Pharmaceuticals is now covered by UBS Group AG. They set a “buy” rating and a $55.00 price target on the stock.
• 6/15/2026 – Crinetics Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $81.00 price target on the stock.
• 6/11/2026 – Crinetics Pharmaceuticals had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $95.00 price target on the stock.

Insiders Place Their Bets

In related news, Director Coelho Rogerio Vivaldi sold 3,000 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $40.00, for a total value of $120,000.00. Following the sale, the director owned 19,225 shares in the company, valued at $769,000. This represents a 13.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephanie Okey sold 6,900 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $35.67, for a total transaction of $246,123.00. Following the completion of the transaction, the director directly owned 6,400 shares in the company, valued at approximately $228,288. The trade was a 51.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.80% of the stock is currently owned by company insiders.

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.